Document Detail

Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy.
MedLine Citation:
PMID:  21911803     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Coronary artery vein graft failure, resulting from thrombosis, intimal thickening, and atherosclerosis, is a significant clinical problem, with approximately 50% of vein grafts failing within 10 years. Intimal thickening is caused by migration of vascular smooth muscle cells from the media to the intima, where they proliferate. Interventions using gene transfer to inhibit vascular smooth muscle cells proliferation and migration are attractive because ex vivo access to the graft is possible. The involvement of matrix-degrading metalloproteinases in intimal thickening is well established, and we previously showed that adenoviral-delivered overexpression of an endogenous inhibitor, the tissue inhibitor of metalloproteinases-3 (TIMP-3), significantly retarded intimal thickening in short-term autologous porcine arteriovenous interposition grafts (28 days). However, it is essential to determine whether this approach will provide longer-term benefits.
METHODS AND RESULTS: We assessed whether a recombinant adenovirus that overexpresses TIMP-3 (RAdTIMP-3) affects vein graft intimal thickening in the longer term (at 3 months). Porcine saphenous veins were subjected to luminal infection with 2.5×10(10) pfu/mL RAdTIMP-3 or RAd60 (control virus) or vehicle control, for 30 minutes before implantation into the carotid artery. Analysis of grafts harvested 3 months after delivery revealed that RAdTIMP-3-infected grafts had significantly reduced intimal areas compared with both controls (3.2 ± 0.4 mm(2) versus 5.6 ± 0.7 mm(2) and 5.9 ± 0.5 mm(2), RAdTIMP-3, RAd60, and vehicle, respectively). Medial areas were also significantly decreased by TIMP-3 (3.8 ± 0.3 mm(2) versus 6.7 ± 1.0 mm(2) and 5.2 ± 0.4 mm(2), RAdTIMP-3, RAd60, and vehicle, respectively).
CONCLUSIONS: Overexpression of TIMP-3 provides a sustained retardation of vein graft intimal thickening and highlights the translational potential for ex vivo TIMP-3 gene therapy.
Sarah J George; Song Wan; Jia Hu; Robert MacDonald; Jason L Johnson; Andrew H Baker
Related Documents :
8237683 - Anatomy of the junction of the inferior petrosal sinus and the internal jugular vein.
6830523 - Nasal polyposis with invasion into the orbit.
25215953 - Successful selective angiographic embolisation of a gastroduodenal pseudoaneurysm follo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  124     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-09-13     Completed Date:  2011-11-03     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S135-42     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoviridae / genetics
Carotid Arteries / metabolism,  pathology,  surgery*
Cell Movement / physiology
Endothelium, Vascular / metabolism,  pathology
Genetic Therapy / methods*
Models, Animal
Muscle, Smooth, Vascular / metabolism,  pathology
Neointima / prevention & control*,  therapy*
Saphenous Vein / metabolism,  pathology,  transplantation*
Time Factors
Tissue Inhibitor of Metalloproteinase-3 / genetics*,  metabolism
Treatment Outcome
Vascular Grafting / methods*
Grant Support
FS/07/053/24069//British Heart Foundation; //British Heart Foundation
Reg. No./Substance:
0/Tissue Inhibitor of Metalloproteinase-3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Off-pump bilateral versus single skeletonized internal thoracic artery grafting in high-risk patient...
Next Document:  Thrombomodulin gene variants are associated with increased mortality after coronary artery bypass su...